Legislation passed by the government of India rarely draws internationalattention, let alone global outrage. But in December 2004, tocomply with the requirement of the World Trade Organization(which India had joined in 1995) that its member countries adhereto trade-related aspects of intellectual property rights (TRIPs),the president of India issued a patent-amendment ordinance requiring20-year patents on all new medications. The ordinance went intoeffect January 1, 2005. Objections were voiced around the worldby advocacy groups for patients with human immunodeficiencyvirus (HIV) infection, who characterized the proposed law aspitting patents against patients. As a . . . [Full Text of this Article]
Source Information
Dr. Havlir is a professor of medicine at the University of California, San Francisco, and chief of the HIV–AIDS Division at San Francisco General Hospital, San Francisco. Dr. Hammer is a professor of medicine at Columbia University College of Physicians and Surgeons and chief of the Division of Infectious Diseases at the Columbia University Medical Center, New York–Presbyterian Hospital, New York.
An interview with Dr. Havlir can be heard at www.nejm.org.
This article has been cited by other articles:
Boulle, A, Ford, N
(2007). Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges?. Sex. Transm. Infect.
83: 503-505
[Full Text]
Bartlett, J. A., Muro, E. P.
(2007). Generic and Branded Drugs for the Treatment of People Living With HIV/AIDS. J Int Assoc Physicians AIDS Care (Chic Ill)
6: 15-23
[Abstract]
Interview
